Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
复制标题
DOI：
10.1056/nejmoa1205099
复制
发表时间：
2012-12-20
影响因子：
158.5
通讯作者：
Lovell, Daniel J.
中科院分区：
文献类型：
--
作者：
Ruperto, Nicolino;Brunner, Hermine I.;Lovell, Daniel J.
背景白细胞介素-1在全身性幼年特发性关节炎（JIA）的发病机制中起关键作用。我们在两项试验中评估了canakinumab的有效性和安全性，canakinumab是一种选择性的、全人源的抗白细胞介素-1 β单克隆抗体。
BACKGROUNDInterleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1 beta monoclonal antibody, in two trials.METHODSIn trial 1, we randomly assigned patients, 2 to 19 years of age, with systemic JIA and active systemic features (fever; >= 2 active joints; C-reactive protein, >30 mg per liter; and glucocorticoid dose,